Member Info for DeBull

Looks like the posters who warned of a further placing were right again.

Here is part of the RNS regarding from Feb 2025:

In order to further develop its business and accelerate growth, the Company is raising funds to carry out the following activities and for general working capital.

· Mathematical Modelling Consulting Service

o Recruitment of further technical team members to accelerate the conversion of the pipeline and support service delivery;

o Investment in Business Development and Marketing to build and strengthen the pipeline, expand into new therapeutic areas, further develop its data science offering and refresh messaging; and

o Explore strategic options to accelerate the growth of modelling services.

· Biostatistics Consulting Service

o Organic growth of the service though Business Development and Marketing to acquire clients; and

o Explore strategic options to accelerate the growth of biostatistics services.

· Personalised Medicine Tool Development

o Explore a deeper relationship with DoseMe to develop models to be implemented on their platform; and

o Implementation of the Company's current personalised dosing tool on the DoseMeRx Platform enabling it to be made available to clinicians across the US.

· General Working Capital

Here is the post from today:

In order to further develop its business and continue its growth trajectory, the Company is raising funds to carry out the following activities and for general working capital:

· Consulting Services (Modelling & Simulation and Biometrics)

o Investment in business development and marketing to expand offering across both service lines, including further development of later clinical phases and engagement of large biopharmaceutical companies and contract research organisations; and

o Expansion of internal capabilities to support both services, including development of new processes and data management solutions to support the expanding offerings.

· Personalised Medicine Tool Development

o Continue development of the Company's Personalised Dosing Software.

· Corporate

o Exploration of strategic options to accelerate growth of modelling and biometrics services and creation of new service-lines.

Is it me or do the 2 descriptions of what the money raised in 2025 and 2026 seem roughly the same? Doseme is not mentioned today, just the dosing software.

I am sure some will see some positives here, but alas, i cant at the moment. I wonder what the % chance is that PI's can stop this dilution?

Guess most will have missed this update from Cellcentric? https://x.com/CellCentric/status/2024461464266805516?s=20

"Inobrodib is our investigational oral drug with a novel MoA. Delivered as a capsule, and used as part of an all-oral regimen with pom/dex (InoPd) for later line patients, it suits community-based care + may improve access for those with later stage #MM. Pivotal studies this year."

PYC helped them several years ago at the beginning of Inobrodib's journey or P300 is think it was called? Its also got "orphan status" as well. This could be a feather in PYC's cap if these "pivotal studies" go well. Will they get any more £ for it? nope, hopefully recognition, but that does not pay the bills!

After reading the interims and the balancing views of Trench/King/Trout there is nothing more i can add, that has not already been said. The SP has had a nice uptick recently, but imho this is nothing to do with contract win(s) etc, its all down to Mike buying and going TR1. Obviously, some of his followers have taken a position to. However, as i have said previously, investors are wary of PYC, its past history of placings, and P&D crews manipulating it to spike, and then fall away. There is only so many times people will think of buying here, then decide they been stung before?

Will Mike will keep buying, if the SP drops lower? Kudos to him for saying he was buying before, and would go TR1, and did. Roll on Docetaxel!

Thanks for the posts King.

Lets hope the rise on Friday is sustained? Came out of nowhere.

Could be a massive P&D gamble by DDS? They have made £ before, but after placings. Is this the 1st time they have put a large amount of cash down on PYC without a placing? Says they are patient with their return timelines of a few days to year, and say "multibags" Also state that a TR1 is incoming? If one arrives, then all good, if not, then you just have to think that what ever they say in the future has to be questioned? We'll know at 0700?

Meanwhile, Docetaxel is still in "development" like it has been for sometime now, and we await "Validation" https://doseme-rx.com/why-dosemerx/drug-packages

Looks like another P&D? I make that 4 times quite recently where the SP has moved quite a few %, only for it to come back to near where it started? As hypothesised before, each time this happens, the smaller the spike is getting, the quicker the money is taken off the table? The more this happens, the more investors are wary, the harder the P&Ders have to work, and only for a few % now. In the old days, a heftier % would be made.

Meanwhile, Docetaxel is still in its "development" stage, its been there for a few years now?? "Validation" has to be nearer every day that passes?

Back in my box i go.

I wish i could argue against you TIO, however i fear i can not, and it looks concerning. I hope history is not going to repeat itself?

Scintillating chat today....not.

The SP did tick up, but only because the MM widened the spread to 39-45, this has happened so many times recently. Goes to 39-40, then 39-45 then back again. Every time the SP looks like it may move out, it gets sold in to. Depending on who you listen to, the SP is either in the doldrums or a coiled spring.

What ever side of the fence you are sitting on, this discussion between Tout, King and Trench is very good Verbal sparring at it best imho

In other news, the Doseme website has a 500 internal server error.

The injection of the 4M trade started off the buying, aided by the MM's horrific spread. As usual PYC zooms off due to low liquidity. Rumours of this and that, i aint seen or heard no rumours.

Dont get me wrong, i want it to be 1p, 2p + etc, but on no news, no chance. Yes we have "6 late stage possible contracts" but they have not landed yet. I am guessing that the 4M buyer got out in drips and drabs in the next hour or so with a 10-15% gain? Not bad for a few hours work, and if you can time it well.

Let me guess how this plays out in the next week or so.... it'll bumble around the upper to mid 40's before falling back to around the 40 level, till it all starts again. If news, then that hypothesis changes. Meanwhile another day closer for Docetaxel.

Back to the .39 level again. Not been this low since middle of April this year? This could go 1 of 2 ways, Yazz or status quo.

Burt, like your optimism.

J, i believe it was all "if" Its not PYC fault the deal between VAL and Theorem RX did not come off yet. They had/have an agreement in place. Again, if it had come to fruition, there would have been a increase in mkt cap? I guess some were trying to inform others of this?

Thank you to Trench and King et al for their opinion and observations of the AR and the IM.

If anyone is reading these posts from the opposite side of the spectrum from Avo and TIO etc, they will be in a quandary as to who to believe?

Someone has to be right? Mind you if you are thinking of putting £ in PYC purely based on BB information then that is a bad idea.

With all this talk of cash positions at certain time frames, cash burn, BOD wages etc its all very confusing, as either side of the argument has their option for one reason of a other.

The thorny question of a discounted fundraise persists? On one side they say no, the other side say yes? In the past, some have said no fund raise will appear, and then when it occurred they were not surprised, only the timing of it.

This and the P&D nature of PYC volatile movements "could" be holding PYC back with investors. TIO mentioned that the P&D aspect of the movements is getting smaller and shorter? I have witnessed that to,. Also seems that the % gains from this kind of trading is getting smaller, as more and more people are getting wise to it? Why risk putting £ in on a spike when the SP can fall back to where it was days later? A few weeks ago i mentioned that we were in the .50 range, and since the AR and IM pres the SP has fallen back, but not to its lows of months ago. Was this a P&D with run up top the AR, was it investors betting on the AR being better than perceived by the wider market after their "exceed market expectations" TU, then bailing?

Can the notion of a fundraise discounted or not, ever be the thing of the past in a microcap, no.

For me the link with Doseme and dealing with Docetaxel is a main driver here.

The conversation rate has nearly doubled in the last year which is impressive.

6 late stage contracts due. If last year is anything to go by, then we should expect all 6 to land at sometime?

Thank you all with their thoughts and counter thoughts on the Results and IM.

I guess the market was subdued by the results?

For me, its the Doseme and Docetaxel awaiting completion.

Think its very good that it held above .50 today, helped with MM not having a wide spread at times. Results next week?

Thank you for the apology TIO. Indeed still in & patiently waiting.

Nice steady rise. Lets hope it not being manipulated by a select few. X is quiet, Telegram is quiet.

People know that PYC can spike big time, not as much as it used to, as more shares in issue. However, all it takes is for a few to get the ball rolling, others pile in, and the originals walk away with a nice return. People maybe getting used to this tactic? A nice steady rise backed by fundamentals & news is good.

Roll on Docetaxel & DoseMe.

Mr / Mrs 1'771'084 lasted less than a hour and lost a few quid to.

Great to see a blue day with some chunky trades appearing.

Can it hold these modest gains? Last few times, the gains have evaporated.

Good to see the BB even keeled after the mini swell over the weekend.

King, that is again a great summary and a personalised vision.

OSD, very good, have you been drinking too much of the wine at communion?

Good to have a follow on contract.

Jun 24 contract was for 5 months av at 32k per month.

Todays is av at £19k per month.

According to Grok "UK-based biotech client at the forefront of AI-driven drug development.” The 3 it lists are Benevolent AI, Exscientia and Healx